Alterations in mGluR5 expression and signaling in lewy body disease and in transgenic models of alpha- synucleinopathy - implications for excitotoxicity

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Price, Diana L ^a,b,c   Rockenstein, Edward ^a   Ubhi, Kiren ^a   Phung, Van ^b   Maclean Lewis, Natalie ^b   Askay, David ^a,b   Cartier, Anna ^a   Spencer, Brian ^a   Patrick, Christina ^a   Desplats, Paula ^a   Ellisman, Mark H ^a,b   Masliah, Eliezer ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ACADIA PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; ALPHA SYNUCLEIN; BETA ARRESTIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; METABOTROPIC RECEPTOR 5; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR ELK 1; 6 METHYL 2 (PHENYLETHYNYL)PYRIDINE; 6-METHYL-2-(PHENYLETHYNYL)PYRIDINE; AMINO ACID RECEPTOR BLOCKING AGENT; METABOTROPIC RECEPTOR; PYRIDINE DERIVATIVE;

AGED; ALPHA SYNUCLEINOPATHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BEHAVIOR DISORDER; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; EXCITOTOXICITY; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MALE; MOTOR CORTEX; MOUSE; NERVE CELL NECROSIS; NONHUMAN; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; PUTAMEN; SIGNAL TRANSDUCTION; ANIMAL; AUTOPSY; BRAIN; DEGENERATIVE DISEASE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MEMORY DISORDER; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; TRANSGENIC MOUSE;

MURINAE; MUS; MUS MUSCULUS;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ANIMALS; AUTOPSY; BRAIN; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LEWY BODY DISEASE; MALE; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PYRIDINES; RECEPTORS, METABOTROPIC GLUTAMATE; SIGNAL TRANSDUCTION;

EID: 78649516910     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014020     Document Type: Article

References (90)

1. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, et al. (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65: 1863-1872.
2. Shastry BS (2001) Parkinson disease: etiology, pathogenesis and future of gene therapy. Neurosci Res 41: 5-12.
3. Irizarry M, Growdon W, Gomez-Isla T, Newell K, George J, et al. (1998) Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alphalpha-synuclein immunoreactivity. JNeuropatholExpNeurol 57: 334-337.
4. Takeda A, Hashimoto M, Mallory M, Sundsmo M, Hansen L, et al. (1998) Abnormal distribution of the non-Ab component of Alzheimer's disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. LabInvest 78: 1169-1177.
5. Takeda A, Mallory M, Sundsmo M, Honer W, Hansen L, et al. (1998) Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. AmJPathol 152: 367-372.
6. Trojanowski J, Goedert M, Iwatsubo T, Lee V (1998) Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and lewy body dementia. Cell Death Differ 5: 832-837.
7. Wakabayashi K, Hayashi S, Kakita A, Yamada M, Toyoshima Y, et al. (1998) Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol 96: 445-452.
8. Wakabayashi K, Matsumoto K, Takayama K, Yoshimoto M, Takahashi H (1997) NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. NeurosciLett 239: 45-48.
9. Dickson D, Crystal H, Mattiace L, Kress Y, Schwagerl A, et al. (1989) Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques. Acta Neuropathol 78: 572-584.
10. Dickson D, Davies P, Mayeux R, Crystal H, Horoupian D, et al. (1987) Diffuse Lewy body disease. Neuropathological and biochemical studies of six patients. Acta Neuropathol 75: 8-15.
11. Braak H, Braak E (2000) Pathoanatomy of Parkinson's disease. J Neurol 247(Suppl 2): II3-10.
12. Lansbury PTJ (1999) Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease. PNAS 96: 3342-3344.
13. Wright PE, Dyson HJ (1999) Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J Mol Biol 293: 321-331.
14. Iwai A, Masliah E, Yoshimoto M, De Silva R, Ge N, et al. (1994) The precursor protein of non-Ab component of Alzheimer's disease amyloid (NACP) is a presynaptic protein of the central nervous system. Neuron 14: 467-475.
15. Murphy D, Reuter S, Trojanowski J, Lee V-Y (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. JNeurosci 20: 3214-3220.
16. Spillantini M, Schmidt M, Lee V-Y, Trojanowski J, Jakes R, et al. (1997) alphasynuclein in Lewy bodies. Nature 388: 839-840.
17. Lee MK, Stirling W, Xu Y, Xu X, Qui D, et al. (2002) Human alphalphasynuclein- harboring familial Parkinson's disease-linked Ala-53 -. Thr mutation causes neurodegenerative disease with alphalpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A 99: 8968-8973.
18. Lee VM, Giasson BI, Trojanowski JQ (2004) More than just two peas in a pod: common amyloidogenic properties of tau and alphalpha-synuclein in neurodegenerative diseases. Trends Neurosci 27: 129-134.
19. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, et al. (2000) Dopaminergic loss and inclusion body formation in alphalpha-synuclein mice: Implications for neurodegenerative disorders. Science 287: 1265-1269.
20. Feany M, Bender W (2000) A Drosophila model of Parkinson's disease. Nature 404: 394-398.
21. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, et al. (2002) Alphalphasynuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322: 1089-1102.
22. Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, et al. (2008) Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS One 3: e3135.
23. Tsigelny IF, Sharikov Y, Miller MA, Masliah E (2008) Mechanism of alphalphasynuclein oligomerization and membrane interaction: theoretical approach to unstructured proteins studies. Nanomedicine 4: 350-357.
24. Sidhu A, Wersinger C, Vernier P (2004) Does alphalpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? Faseb J 18: 637-647.
25. Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, et al. (2002) A role for alphalphasynuclein in the regulation of dopamine biosynthesis. J Neurosci 22: 3090-3099.
26. Rochet JC, Outeiro TF, Conway KA, Ding TT, Volles MJ, et al. (2004) Interactions among alphalpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci 23: 23-34.
27. Outeiro TF, Klucken J, Bercury K, Tetzlaff J, Putcha P, et al. (2009) Dopamineinduced conformational changes in alphalpha-synuclein. PLoS One 4: e6906.
28. Yamakawa K, Izumi Y, Takeuchi H, Yamamoto N, Kume T, et al. (2010) Dopamine facilitates alphalpha-synuclein oligomerization in human neuroblastoma SH-SY5Y cells. Biochem Biophys Res Commun 391: 129-134.
29. Greenamyre JT (2001) Glutamatergic influences on the basal ganglia. Clin Neuropharmacol 24: 65-70.
30. Rouse ST, Marino MJ, Bradley SR, Awad H, Wittmann M, et al. (2000) Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol Ther 88: 427-435.
31. Tisch S, Silberstein P, Limousin-Dowsey P, Jahanshahi M (2004) The basal ganglia: anatomy, physiology, and pharmacology. Psychiatr Clin North Am 27: 757-799.
32. Lee HG, Zhu X, O'Neill MJ, Webber K, Casadesus G, et al. (2004) The role of metabotropic glutamate receptors in Alzheimer's disease. Acta Neurobiol Exp (Wars) 64: 89-98.
33. Feeley Kearney JA, Albin RL (2003) mGluRs: a target for pharmacotherapy in Parkinson disease. Exp Neurol 184(Suppl 1): S30-36.
34. Marino MJ, Valenti O, Conn PJ (2003) Glutamate receptors and Parkinson's disease: opportunities for intervention. Drugs Aging 20: 377-397.
35. Naie K, Manahan-Vaughan D (2004) Regulation by metabotropic glutamate receptor 5 of LTP in the dentate gyrus of freely moving rats: relevance for learning and memory formation. Cereb Cortex 14: 189-198.
36. Simonyi A, Schachtman TR, Christoffersen GR (2005) The role of metabotropic glutamate receptor 5 in learning and memory processes. Drug News Perspect 18: 353-361.
37. Romano C, Sesma MA, McDonald CT, O'Malley K, Van den Pol AN, et al. (1995) Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol 355: 455-469.
38. Chase TN, Oh JD (2000) Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 23: S86-91.
39. Ossowska K, Konieczny J, Wolfarth S, Wieronska J, Pilc A (2001) Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian- like effects in rats. Neuropharmacology 41: 413-420.
40. Phillips JM, Lam HA, Ackerson LC, Maidment NT (2006) Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease. Eur J Neurosci 23: 151-160.
41. Popoli P, Pezzola A, Torvinen M, Reggio R, Pintor A, et al. (2001) The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6- hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors. Neuropsychopharmacology 25: 505-513.
42. Aguirre JA, Kehr J, Yoshitake T, Liu FL, Rivera A, et al. (2005) Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP. Brain Res 1033: 216-220.
43. Battaglia G, Busceti CL, Molinaro G, Biagioni F, Storto M, et al. (2004) Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Neurosci 24: 828-835.
44. Rascovsky K, Salmon DP, Ho GJ, Galasko D, Peavy GM, et al. (2002) Cognitive profiles differ in autopsy-confirmed frontotemporal dementia and AD. Neurology 58: 1801-1808.
45. Salmon D, Thal L, Butters N, Heindel W (1990) Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standarized mental status examinations. Neurology 40: 1225-1230.
46. Hansen L, Samuel W (1997) Criteria for Alzheimer disease and the nosology of dementia with Lewy bodies. Neurology 48: 126-132.
47. Galasko D, Katzman R, Salmon DP, Hansen L (1996) Clinical and neuropathological findings in Lewy body dementias. Brain Cogn 31: 166-175.
48. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, et al. (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47: 1113-1124.
49. Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, et al. (2002) Differential neuropathological alterations in transgenic mice expressing alphalpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 68: 568-578.
50. Gasparini F, Lingenhohl K, Stoehr N, Flor PJ, Heinrich M, et al. (1999) 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38: 1493-1503.
51. Kachroo A, Orlando LR, Grandy DK, Chen JF, Young AB, et al. (2005) Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J Neurosci 25: 10414-10419.
52. McGeehan AJ, Janak PH, Olive MF (2004) Effect of the mGluR5 antagonist 6- methyl-2-(phenylethynyl)pyridine (MPEP) on the acute locomotor stimulant properties of cocaine, D-amphetamine, and the dopamine reuptake inhibitor GBR12909 in mice. Psychopharmacology (Berl) 174: 266-273.
53. Fernagut PO, Chalon S, Diguet E, Guilloteau D, Tison F, et al. (2003) Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice. Neuroscience 116: 1123-1130.
54. Matsuura K, Kabuto H, Makino H, Ogawa N (1997) Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods 73: 45-48.
55. Rockenstein E, Adame A, Mante M, Moessler H, Windisch M, et al. (2003) The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. J Neural Transm 110: 1313-1327.
56. Mattila PM, Rinne JO, Helenius H, Dickson DW, Roytta M (2000) Alphalphasynuclein- immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol 100: 285-290.
57. Chow SK, Hakozaki H, Price DL, MacLean NA, Deerinck TJ, et al. (2006) Automated microscopy system for mosaic acquisition and processing. J Microsc 222: 76-84.
58. Price DL, Chow SK, Maclean NA, Hakozaki H, Peltier S, et al. (2006) Highresolution large-scale mosaic imaging using multiphoton microscopy to characterize transgenic mouse models of human neurological disorders. Neuroinformatics 4: 65-80.
59. Fan GY, Fujisaki H, Miyawaki A, Tsay RK, Tsien RY, et al. (1999) Video-rate scanning two-photon excitation fluorescence microscopy and ratio imaging with cameleons. Biophys J 76: 2412-2420.
60. Dale LB, Babwah AV, Ferguson SS (2002) Mechanisms of metabotropic glutamate receptor desensitization: role in the patterning of effector enzyme activation. Neurochem Int 41: 319-326.
61. Dale LB, Bhattacharya M, Seachrist JL, Anborgh PH, Ferguson SS (2001) Agonist-stimulated and tonic internalization of metabotropic glutamate receptor 1a in human embryonic kidney 293 cells: agonist-stimulated endocytosis is betaarrestin1 isoform-specific. Mol Pharmacol 60: 1243-1253.
62. Mundell SJ, Matharu AL, Pula G, Roberts PJ, Kelly E (2001) Agonist-induced internalization of the metabotropic glutamate receptor 1a is arrestin- and dynamin-dependent. J Neurochem 78: 546-551.
63. Ohno Y, Ishida K, Ikeda K, Ishibashi T, Okada K, et al. (1994) Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test. Pharmacol Biochem Behav 49: 19-23.
64. Sanchez-Pernaute R, Wang JQ, Kuruppu D, Cao L, Tueckmantel W, et al. (2008) Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates. Neuroimage 42: 248-251.
65. Aronica E, Catania MV, Geurts J, Yankaya B, Troost D (2001) Immunohistochemical localization of group I and II metabotropic glutamate receptors in control and amyotrophic lateral sclerosis human spinal cord: upregulation in reactive astrocytes. Neuroscience 105: 509-520.
66. Oka A, Takashima S (1999) The up-regulation of metabotropic glutamate receptor 5 (mGluR5) in Down's syndrome brains. Acta Neuropathol 97: 275-278.
67. Lee HG, Ogawa O, Zhu X, O'Neill MJ, Petersen RB, et al. (2004) Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer's disease. Acta Neuropathol 107: 365-371.
68. Lee HG, Zhu X, Ghanbari HA, Ogawa O, Raina AK, et al. (2002) Differential regulation of glutamate receptors in Alzheimer's disease. Neurosignals 11: 282-292.
69. Thorns V, Mallory M, Hansen L, Masliah E (1997) Alterations in glutamate receptor 2/3 subunits and amyloid precursor protein expression during the course of Alzheimer's disease and Lewy body variant. Acta Neuropathol 94: 539-548.
70. Hilton GD, Nunez JL, Bambrick L, Thompson SM, McCarthy MM (2006) Glutamate-mediated excitotoxicity in neonatal hippocampal neurons is mediated by mGluR-induced release of Ca++ from intracellular stores and is prevented by estradiol. Eur J Neurosci 24: 3008-3016.
71. Nicoletti F, Bruno V, Copani A, Casabona G, Knopfel T (1996) Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci 19: 267-271.
72. Bruno V, Battaglia G, Copani A, D'Onofrio M, Di Iorio P, et al. (2001) Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J Cereb Blood Flow Metab 21: 1013-1033.
73. O'Leary DM, Movsesyan V, Vicini S, Faden AI (2000) Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br J Pharmacol 131: 1429-1437.
74. Rylander D, Iderberg H, Li Q, Dekundy A, Zhang J, et al. (2010) A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis.
75. Breysse N, Amalric M, Salin P (2003) Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats. J Neurosci 23: 8302-8309.
76. Breysse N, Baunez C, Spooren W, Gasparini F, Amalric M (2002) Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 22: 5669-5678.
77. Coccurello R, Breysse N, Amalric M (2004) Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology 29: 1451-1461.
78. Turle-Lorenzo N, Breysse N, Baunez C, Amalric M (2005) Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease. Psychopharmacology (Berl) 179: 117-127.
79. Gregoire L, Samadi P, Graham J, Bedard PJ, Bartoszyk GD, et al. (2009) Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. Parkinsonism Relat Disord 15: 445-452.
80. Ouattara B, Gasparini F, Morissette M, Gregoire L, Samadi P, et al. (2010) Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys. J Neurochem 113: 715-724.
81. De Leonibus E, Manago F, Giordani F, Petrosino F, Lopez S, et al. (2009) Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease. Neuropsychopharmacology 34: 729-738.
82. Nafia I, Re DB, Masmejean F, Melon C, Kachidian P, et al. (2008) Preferential vulnerability of mesencephalic dopamine neurons to glutamate transporter dysfunction. J Neurochem 105: 484-496.
83. Halliday GM, Macdonald V, Henderson JM (2005) A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. Brain 128: 2272-2280.
84. Harding AJ, Halliday GM (2001) Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol (Berl) 102: 355-363.
85. Harding AJ, Lakay B, Halliday GM (2002) Selective hippocampal neuron loss in dementia with Lewy bodies. Ann Neurol 51: 125-128.
86. Conn PJ, Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37: 205-237.
87. Mattson MP (2007) Calcium and neurodegeneration. Aging Cell 6: 337-350.
88. Iwata A, Miura S, Kanazawa I, Sawada M, Nukina N (2001) alphalphasynuclein forms a complex with transcription factor Elk-1. J Neurochem 77: 239-252.
89. Zhu JH, Kulich SM, Oury TD, Chu CT (2002) Cytoplasmic aggregates of phosphorylated extracellular signal-regulated protein kinases in Lewy body diseases. Am J Pathol 161: 2087-2098.
90. Iwata A, Maruyama M, Kanazawa I, Nukina N (2001) alphalpha-synuclein affects the MAPK pathway and accelerates cell death. J Biol Chem 276: 45320-45329.